Dr Ana M. Gonzalez-Angula - Department of Breast Medical Oncology, Department of Systems Biology at the University of Texas M.D. Anderson Cancer Center
Although current guidelines call for no further therapy after surgery on breast tumours one
centimeter or smaller, a new study suggests that if these tumors are HER2 positive
patients have an increased risk for relapse. In the largest study of its kind to date
(n=1,315, including a validation set), researchers found that the five-year recurrence rate
was 23 percent among patients with small HER2-positive tumours, compared with eight
percent in other tumour types. Speaking at San Antonio Breast Cancer symposium 2008.